Please login to the form below

Not currently logged in
Email:
Password:

IFPMA appoints director general

Thomas Cueni brings expertise from Interpharma and EFPIA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has selected Thomas Cueni as its new director general.

Cueni takes on responsibility for representing the interests of the research-based pharma industry at a global level, working with organisations and governments to promote the value of pharmaceutical innovation and improve access to treatments.

He brings considerable experience as secretary general of Interpharma, the Basel-based association representing Swiss pharma firms, during which time he had been closely associated with IFPMA as a member of its council.

Cueni also brings industry expertise from the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he served in a policy-shaping and advocacy capacity.

Ian Read, IFPMA's president and chief executive and chairman of Pfizer, said: “Thomas has extensive experience in the research-based biopharmaceutical industry and a deep understanding of what is needed to support the continued discovery and development of important life-saving and life-enhancing medicines and vaccines.

“I look forward to working closely with Thomas in advocating for sustainable health policies that foster innovation and ensure patient access to these important advances.”

8th February 2017

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics